skip to main content
Idioma:

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Knobler, R. ; Moinzadeh, P. ; Hunzelmann, N. ; Kreuter, A. ; Cozzio, A. ; Mouthon, L. ; Cutolo, M. ; Rongioletti, F. ; Denton, C.P. ; Rudnicka, L. ; Frasin, L.A. ; Smith, V. ; Gabrielli, A. ; Aberer, E. ; Bagot, M. ; Bali, G. ; Bouaziz, J. ; Braae Olesen, A. ; Foeldvari, I. ; Frances, C. ; Jalili, A. ; Just, U. ; Kähäri, V. ; Kárpáti, S. ; Kofoed, K. ; Krasowska, D. ; Olszewska, M. ; Orteu, C. ; Panelius, J. ; Parodi, A. ; Petit, A. ; Quaglino, P. ; Ranki, A. ; Sanchez Schmidt, J.M. ; Seneschal, J. ; Skrok, A. ; Sticherling, M. ; Sunderkötter, C. ; Taieb, A. ; Tanew, A. ; Wolf, P. ; Worm, M. ; Wutte, N.J. ; Krieg, T.

Journal of the European Academy of Dermatology and Venereology, 2017-09, Vol.31 (9), p.1401-1424 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
  • Título:
    European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
  • Autor: Knobler, R. ; Moinzadeh, P. ; Hunzelmann, N. ; Kreuter, A. ; Cozzio, A. ; Mouthon, L. ; Cutolo, M. ; Rongioletti, F. ; Denton, C.P. ; Rudnicka, L. ; Frasin, L.A. ; Smith, V. ; Gabrielli, A. ; Aberer, E. ; Bagot, M. ; Bali, G. ; Bouaziz, J. ; Braae Olesen, A. ; Foeldvari, I. ; Frances, C. ; Jalili, A. ; Just, U. ; Kähäri, V. ; Kárpáti, S. ; Kofoed, K. ; Krasowska, D. ; Olszewska, M. ; Orteu, C. ; Panelius, J. ; Parodi, A. ; Petit, A. ; Quaglino, P. ; Ranki, A. ; Sanchez Schmidt, J.M. ; Seneschal, J. ; Skrok, A. ; Sticherling, M. ; Sunderkötter, C. ; Taieb, A. ; Tanew, A. ; Wolf, P. ; Worm, M. ; Wutte, N.J. ; Krieg, T.
  • Assuntos: Diagnosis, Differential ; Europe ; Humans ; Physical Examination ; Prognosis ; Scleroderma, Localized - diagnosis ; Scleroderma, Localized - pathology ; Scleroderma, Localized - therapy ; Scleroderma, Systemic - diagnosis ; Scleroderma, Systemic - pathology ; Scleroderma, Systemic - therapy ; Undifferentiated Connective Tissue Diseases - diagnosis ; Undifferentiated Connective Tissue Diseases - pathology ; Undifferentiated Connective Tissue Diseases - therapy
  • É parte de: Journal of the European Academy of Dermatology and Venereology, 2017-09, Vol.31 (9), p.1401-1424
  • Notas: Prof. Dr. Maurizio Cutolo received research grants from Actelion, Bristol‐Myers Squibb, Horizon and Mundipharma.
    Prof. Dr. Lidia Rudnicka is consultant for diverse Polish governmental institutions from which she also received research grants.
    Prof. Dr. Aurora Parodi has board membership with Galderma, Novartis, AbbVie and Pfizer; received payment for expert testimony from Pfizer, Novartis, Janssen Cilag and AbbVie; research grants from Pfizer; speakers' fees from UCB Pharma and Novartis; and payment for manuscript preparation from Almirall and Galderma.
    Prof. Dr. Luc Mouthon has board membership with Actelion, received a research grant from CSL Behring and payment for lectures and for development of educational presentations from Actelion, Roche and LFB Biomedicaments.
    Prof. Dr. Margitta Worm received consultancy fees and support for travel to meetings from Actelion.
    Prof. Dr. Sarolta Kárpáti received consultancy fees from Janssen‐Cilag and AbbVie and a research grant from Bristol‐Myers Squibb and has relationships with Roche, Novartis and Amgen.
    Dr. Catherine Orteu is consultant for Shire Human Genetic Therapies from where she also received speakers' fees and received grants form Dermatrust, Royal Free NHS Foundation Trust and Rosetrees Trust.
    Prof. Dr. Jean‐David Bouaziz has board membership with Novartis, Lilly and Neovacs, received grants from Therakos/Mallinckrodt and support for travel to meetings from AbbVie.
    Dr. Michael Sticherling received research grants from Novartis; consultancy fees from AbbVie, Actelion Amgen, Celgene, Janssen‐Cilag, Leo Pharma, Lilly, Pfizer, Merck Sharp & Dohme, Mundipharma and Novartis; payment for lectures from AbbVie, Actelion Celgene, Janssen‐Cilag, Leo Pharma, Pfizer, Merck Sharp & Dohme, Novartis and Dermapharm; payment for manuscript preparation from Janssen‐Cilag; and royalties from Becton‐Dickinson.
    Prof. Dr. Vanessa Smith received research grants from Actelion, Boehringer Ingelheim, Roche/Genentech, Galapagos NV and Merck Sharp & Dohme.
    Dr. Ivan Foeldvari received consulting honoraria from AbbVie, Chugai Pharma, Bayer, Roche/Genentech and Novartis and support for travel to meetings from Novartis, Bayer and AbbVie.
    Prof. Dr. Robert Knobler received consultancy fees from Therakos/Mallinckrodt and Actelion.
    Prof. Dr. Cord Sunderkötter received research grants from Actelion, Novartis, Boehringer Ingelheim, Roche/Genentech, Galderma, Pfizer and Bristol‐Myers Squibb.
    Conflicts of interest
    Prof. Dr. Thomas Krieg received research grants and payment for participation in review activities as well as for lectures from Actelion. All other authors have no potential conflict of interests to declare.
    Prof. Dr. Camille Frances received payment for lectures form Actelion and Novartis.
    Funding Sources
    Prof. Dr. Armando Gabrielli received support for travel to meetings from Roche, AbbVie, Actelion and Pfizer.
    Dr. Malgorzata Olszewska received grants from Polish governmental institutions.
    Prof. Dr. Nicolas Hunzelmann received lecture fees from Actelion, Bayer and Roche.
    Prof. Dr. Christopher Denton received research grants from Actelion, Roche and CSL Behring, and consulting fees from Actelion, Glaxo Smith Kline, Bayer and Roche.
    Dr. Ulrike Just received support for travel to meetings from Therakos/Mallinckrodt.
    Prof. Dr. Elisabeth Aberer received support for travel to meetings from Glaxo Smith Kline, Allmiral, Bayer and Ratiopharm.
    Prof. Dr. Alexander Kreuter received fees for lectures and manuscript preparation from Actelion and had advisory board membership with Sanofi Pasteur, Merck Sharp & Dohme and AbbVie.
    Dr. Antoine Petit received consultancy fees from Roche, Shire Human Genetic Therapies and HRA Pharma; payment for manuscript preparation from Janssen, Glaxo Smith Kline, Pfizer and Merck Sharp & Dohme; and support for travel to meetings from Janssen‐Cilag, Novartis, Glaxo Smith Kline, Merck Sharp & Dohme, Abbott and Pfizer. Prof.
    Prof. Dr. Kristian Kofoed has board membership with Janssen‐Cilag, AbbVie, Celgene, Novartis, Sanofi Pasteur, Merck Sharp & Dohme and Leo Pharma; received research grants from Novartis, Sanofi Pasteur and Merck Sharp & Dohme; speakers fees from Pfizer, Janssen‐Cilag, AbbVie, Meda, Eli Lilly, Sanofi Pasteur, Merck Sharp & Dohme, Gilead and Leo Pharma; payment for manuscript preparation and development of educational presentations from Sanofi Pasteur and Merck Sharp & Dohme; and support for travel to meetings from Eli Lilly, Pfizer, AbbVie and Janssen‐Cilag.
    Dr. Pia Moinzadeh received a research grant, consulting honoraria and fees for lectures and participation in review activities from Actelion.
    Prof. Dr. Ahmad Jalili received consultancy fees from Eli Lilly, Leo Pharma and Novartis and payment for lectures from Eli Lilly, Leo Pharma, Novartis, Janssen‐Cilag and AbbVie.
    Prof. Dr. Peter Wolf received consultancy fees and support for travel to meetings from Therakos/Mallincrodt.
    Prof. Dr. Martine Bagot received support for travel to meetings from Pfizer, Janssen‐Cilag and Novartis for travel to scientific meetings.
    None declared.
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    ObjectType-Instructional Material/Guideline-3
  • Descrição: The term ‘sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first‐ and advanced‐line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.
  • Editor: England
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.